Hemostemix Inc's stock is experiencing a significant downturn, raising concerns among investors.
Hemostemix Inc (HEM.V) has seen its stock price drop by 7.69% in today's trading session, closing at CA$0.06. This decline comes amidst a lack of positive news and investor uncertainty in the small-cap biotech sector.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Hemostemix Inc
HEM.V
HEM.V
Hemostemix Inc
WealthAwesomeMarket cap
$13.32M
52W high
$0.14
52W low
$0.04
1W change
-7.69%
Beta
0.62
Analyst Price Targets
Based on analyst covering HEM
Wall Street analysts forecast HEM stock price to rise 1500.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.96
+1500.0% Upside
Current Price
C$0.06
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HEM's historical volatility
30-Day Vol
132.6%
Annualized
90-Day Vol
110.5%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.05
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.06 | C$0.04 โ C$0.09 |
| 60 trading days | C$0.05 | C$0.03 โ C$0.10 |
| 90 trading days | C$0.05 | C$0.02 โ C$0.11 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should be cautious as Hemostemix faces challenges in maintaining its stock value amid ongoing market volatility and limited news flow.
Stock down 7.69% today
Hemostemix's market cap now stands at approximately CA$13.32 million, reflecting investor concerns over its financial health.
Bull case
If Hemostemix can successfully advance its clinical trials and secure additional funding, there could be a chance for its stock price to recover in the long run.
Bear case
On the flip side, ongoing weakness in the stock price might signal deeper issues within the company, especially if it struggles to build investor confidence or meet its clinical goals.
Market Reaction
The market reacted negatively to Hemostemix's recent actions, including private placements that raised funds at lower share prices. Investors are likely worried about share dilution and whether the company can effectively use the capital it raised.
Investor Sentiment
Investor sentiment seems to be shifting as the stock continues to decline. With no significant news to boost confidence, many are questioning the viability of Hemostemix's business model and its long-term prospects in the competitive biotech landscape.
Looking Ahead
As Hemostemix Inc navigates this downturn, investors will be closely watching for any announcements about its clinical trials and partnerships. The company's ability to regain momentum will depend heavily on its operational progress and strategic decisions moving forward.
Advertisement
